Hemifacial Spasm Market Research Report- Forecast till 2030

Hemifacial Spasm Market Research Information: By Diagnosis (Mri, Ct Or Cat Scan, Angiography (Arteriography)), Treatment (Medical Treatment, Surgical Treatment, Combinational Therapy, Tens, Physical Therapy, Others), End User - Forecast Till 2030

ID: MRFR/MED/4086-HCR | 85 Pages | Author: Rahul Gotadki | March 2024         

Hemifacial Spasm Market Speak to Analyst Request a Free Sample

Hemifacial Spasm Market Scenario:


The Hemifacial Spasm Market is anticipated to reach USD 3170 Million by 2030 at 5.4% CAGR during the forecast period 2022-2030.Hemifacial spasm is a painless neurological condition characterized by persistent or brief involuntary contractions of the muscles innervated by the facial nerve. Vascular compression triggers the primary hemifacial spasm, and secondary hemifacial spasm comprises all other causes of facial nerve damage.


According to the study published in The Scientific World Journal in 2014, it is found that hemifacial spasm is prevalent in 9.8 per 100,000 individuals, and the average age for the onset of hemifacial spasm is 44 years. It is also reported that women and Asian populations have a high susceptibility to hemifacial spasm.


It is noted that increasing technological advancements and growing awareness are the key factors driving the hemifacial spasm market. Nowadays, people are becoming more aware of different types of neurological disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. Thus, increasing awareness has provided a push to the growth of the market.


Various other factors such as increased incidence of craniofacial tremor, and facial chorea, unmet medical needs, increasing government assistance, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement are continuously contributing to the growth of the hemifacial spasm market.


Despite these drivers, there are some issues associated with hemifacial spasm market. The difficult diagnosis, cost of treatment, side-effects of botulinum toxin, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.


Research Methodology:


 Hemifacial Spasm


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience:



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


Segmentation:


The hemifacial spasm market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of the diagnosis, the hemifacial spasm market is classified as magnetic resonance imaging (MRI), computed tomography (CT or CAT scan), angiography (Arteriography), and others.


On the basis of the treatment, the hemifacial spasm market is classified as medical treatment, surgical treatment, combinational therapy, transcutaneous electric nerve stimulation (TENS) therapy, physical therapy, and others. The medical treatment is further classified into Botulinum Neurotoxin (BoNT) Injections and Pharmaceuticals. The sub-segment of Botulinum Neurotoxin (BoNT) Injections includes BoNT-A, BoNT-B, onabotulinumtoxinA, incobotulinumtoxinA, and rimabotulinumtoxinB. The sub-segment of pharmaceuticals include anticonvulsants and GABAergic drugs. The surgical treatment is further classified into microvascular decompression (MVD), and others.


On the basis of the end user, the hemifacial spasm market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.


Regional Analysis:


The Americas dominate the hemifacial spasm market owing to the rising technological advancements and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion, and hospital care accounted for a share of 32.3%.


Europe holds the second position in the hemifacial spasm market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the European market.


The Asia Pacific is the fastest growing hemifacial spasm market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015. An increasing prevalence rate among Asian population is also propelling the growth of the market.


The Middle East & Africa holds the lowest share of the global market due to lack of technical knowledge and poor medical facilities.


Key Players:


Some of key the players in the hemifacial spasm market are Abbott, Allergan, Inc., Cephalon Inc., GlaxoSmithKline plc, Ipsen Group, Johnson & Johnson Services, Inc., Medytox,Inc., Merz Pharma GmbH and Co. KGaA, Novartis AG, Pfizer, Revance Therapeutics, Inc., ROCHE, Sanofi S.A, Shire plc, Stryker, Sunovion Pharmaceuticals, Inc., UCB S.A., US WorldMeds, LLC., and Valeant Pharmaceuticals International, Inc.

Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 3170 Million
  CAGR   5.4% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott, Allergan, Inc., Cephalon Inc., GlaxoSmithKline plc, Ipsen Group, Johnson & Johnson Services, Inc., Medytox,Inc., Merz Pharma GmbH and Co. KGaA, Novartis AG, Pfizer, Revance Therapeutics, Inc., ROCHE, Sanofi S.A, Shire plc, Stryker, Sunovion Pharmaceuticals, Inc., UCB S.A., US WorldMeds, LLC., and Valeant Pharmaceuticals International, Inc.
  Key Market Opportunities   Increased incidence of craniofacial tremor, and facial chorea   Unmet medical needs   Increasing government assistance   Improving regulatory framework   Increasing adoption rate   Rising funding and reimbursement
  Key Market Drivers   Increasing technological advancements   Growing awareness




Frequently Asked Questions (FAQ) :

A Hemifacial Spasm Is A Painless Neurological Condition Characterized By Persistent Or Brief Involuntary Contractions Of The Muscles Innervated By The Facial Nerve.

Hemifacial Spasm Market is expected to exhibit a strong 5.4% CAGR over the Forecast Period From 2022 to 2030.

Rising Incidence of Craniofacial Tremors And Increasing Availability Of Reimbursement For Hemifacial Spasm Treatments Are The Major Drivers For The Global Hemifacial Spasm Market.

The Americas are the dominant force in the Global Hemifacial Spasm Market.

Leading Players in the Hemifacial Spasm Market Include Allergan, Abbott, and Cephalon, among others.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid